All In Biotech

Drug Trial Radar · NCT07903636

QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2027

Study completion Dec 1, 2028

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-arm, phase II clinical trial evaluating the efficacy and safety of QLS4131 in patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD).

Conditions

  • Multiple Myeloma (MM)

Interventions

  • QLS4131Drug

    Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From the first dose to the end of Cycle 24 (each cycle is 28 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, 300000

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.